Last reviewed · How we verify

amlodipine, hydralazine, terazosin or hydrochlorothiazide — Competitive Intelligence Brief

amlodipine, hydralazine, terazosin or hydrochlorothiazide (amlodipine, hydralazine, terazosin or hydrochlorothiazide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (calcium channel blocker, direct vasodilator, alpha-1 antagonist, th

marketed Antihypertensive combination (calcium channel blocker, direct vasodilator, alpha-1 antagonist, thiazide diuretic) L-type calcium channel (amlodipine); vascular smooth muscle (hydralazine); alpha-1 adrenergic receptor (terazosin); sodium-chloride cotransporter (hydrochlorothiazide) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

amlodipine, hydralazine, terazosin or hydrochlorothiazide (amlodipine, hydralazine, terazosin or hydrochlorothiazide) — Tulane University School of Medicine. This is a combination of four distinct antihypertensive agents that lower blood pressure through different mechanisms: calcium channel blockade, vasodilation, alpha-1 adrenergic blockade, and diuresis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
amlodipine, hydralazine, terazosin or hydrochlorothiazide TARGET amlodipine, hydralazine, terazosin or hydrochlorothiazide Tulane University School of Medicine marketed Antihypertensive combination (calcium channel blocker, direct vasodilator, alpha-1 antagonist, thiazide diuretic) L-type calcium channel (amlodipine); vascular smooth muscle (hydralazine); alpha-1 adrenergic receptor (terazosin); sodium-chloride cotransporter (hydrochlorothiazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (calcium channel blocker, direct vasodilator, alpha-1 antagonist, thiazide diuretic) class)

  1. Tulane University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amlodipine, hydralazine, terazosin or hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-hydralazine-terazosin-or-hydrochlorothiazide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: